Table 2.

Clinical and genetic characteristics of acute leukemia with EP300-ZNF384 fusion (continuation of Table 1)

Case	Fusion	Breakpoint	Treatment	Chemotherapy regimen	CR	Current status	Follow-up from determination of EP300-ZNF384 fusion (months)	Follow-up from diagnosis (months)
1	EP300-ZNF384	Ex6-Ex3	Chemotherapy, Allo-HSCT	VDCLP	Yes	Alive	26	84
2	EP300-ZNF384	Ex6-Ex3	Chemotherapy	VDCLP	Yes	Alive	30	30
3	EP300-ZNF384	Ex6-Ex3	Chemotherapy, Allo-HSCT	VDCLP	Yes	Alive	24	24
4	EP300-ZNF384	Ex6-Ex3, Ex6-Ex2	Chemotherapy	VDCLP-like	Yes	Alive	19	19
5	EP300-ZNF384	Ex6-Ex3	Chemotherapy	MAVP	No	Died	1	1
6	EP300-ZNF384	Ex6-Ex3, Ex6-Ex2	Chemotherapy	VDCLP	Yes	Alive	20	20
7	EP300-ZNF384	Ex6-Ex3	Chemotherapy, CarT, Allo-HSCT	VDCLP	No	Died	21	21
8	EP300-ZNF384	Ex6-Ex2	Chemotherapy, CarT, B-ALLo-HSCT	VACLP	No	Died	35	83
9	EP300-ZNF384	Ex6-Ex3	Chemotherapy, Allo-HSCT	VDCLP	Yes	Alive	36	36
10	EP300-ZNF384	Ex6-Ex3	Chemotherapy, Allo-HSCT	VDCLP	Yes	Alive	46	46

CR, complete remission; Ex, exon; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; CarT, chimeric antigen receptor (CAR) T cell therapy; VDCLP, vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone; MAVP, mitoxantrone, cytarabine, vincristine, and prednisone; VACLP, vincristine, cytarabine, cyclophosphamide, L-asparaginase, and prednisone